Optimizing expression of active botulinum toxin type A

Details for Australian Patent Application No. 2005271372 (hide)

Owner Allergan, Inc.

Inventors Aoki, Kei Roger; Li, Shengwen; Steward, Iance E.; Miller, Ronald G.; Gilmore, Marcella A.; Fernandez-Salas Ester E.

Agent Davies Collison Cave

Pub. Number AU-B-2005271372

PCT Pub. Number WO2006/017749

Priority 60/599,121 04.08.04 US

Filing date 3 August 2005

Wipo publication date 16 February 2006

Acceptance publication date 3 May 2012

International Classifications

C12N 15/00 (2006.01) Mutation or genetic engineering

A61K 39/08 (2006.01) Medicinal preparations containing antigens or antibodies - Clostridium, e.g. Clostridium tetani

C07K 14/33 (2006.01) Peptides having more than 20 amino acids

Event Publications

1 March 2007 PCT application entered the National Phase

  PCT publication WO2006/017749 Priority application(s): WO2006/017749

3 May 2012 Application Accepted

  Published as AU-B-2005271372

30 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005271385-Method of preparing a composite image with non-uniform resolution

2005271365-Method and apparatus for predicting properties of a chemical mixture